ARCHIVES

Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable

This article is from The Cancer Letter archive.

Vol. 26 No. 1 | January 31, 2003

Download PDF Visit The Full Archive

Related Articles

Varmus, Branscomb Win Public Service Award From NSF; NCI Clarifies Plans For Large R01s

June 1, 2001

Aventis, MediGene In Pact For Development Of Vaccine.

February 25, 2000

HHS: Gallo Committed Scientific Misconduct In AIDS Virus Discovery

January 8, 1993

ACD Honors Sullivan, Who Reaffirms Anti-Smoking Effort

June 29, 1990

Daily Aspirin May Reduce Risk By 20 Percent, Study Says

February 28, 2014

ODAC Clarifies Standards for Maintenance In Ovarian Cancer; Nixes Olaparib in 11-2 Vote

June 27, 2014